Advertisement

Topics

ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings

12:00 EST 7 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ER...

Other Sources for this Article

ERYTECH
Gil Beyen
Chairman and CEO
Eric Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
or
The Ruth Group
Lee Roth, +1 646 536 7012
Investor relations
lroth@theruthgroup.com
or
Kirsten Thomas, +1 508 280 6592
Media relations
kthomas@theruthgroup.com
or
NewCap
Julien Perez
Investor relations
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

NEXT ARTICLE

More From BioPortfolio on "ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings"

Advertisement
Quick Search
Advertisement
Advertisement